Clearmind Medicine Inc.

NasdaqCM CMND

Clearmind Medicine Inc. Cash and Short-Term Investments for the year ending October 31, 2023: USD 4.01 M

Clearmind Medicine Inc. Cash and Short-Term Investments is USD 4.01 M for the year ending October 31, 2023, a 1,139.88% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Clearmind Medicine Inc. Cash and Short-Term Investments for the year ending October 31, 2022 was USD 323.03 K.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqCM: CMND

Clearmind Medicine Inc.

CEO	Dr. Adi Zuloff-Shani Ph.D.
IPO Date	Nov. 15, 2022
Location	Canada
Headquarters	1220 West 6th Avenue
Employees	4
Sector	Health Care
Industries Pharmaceuticals Mental Health

Description

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Key trends

Past 5 years